These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36769210)

  • 1. Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology.
    Pereira M; Vale N
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of Rilpivirine Resistance-Associated Mutation: E138 in Reverse Transcriptase among Antiretroviral-Naive HIV-1-Infected Individuals in Turkey.
    Sayan M; Sultanoglu N; Sanlidag T
    AIDS Res Hum Retroviruses; 2023 Feb; 39(2):84-90. PubMed ID: 36301912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of Zika Virus Infection in the Brain by the Antiretroviral Drug Rilpivirine.
    Sariyer IK; Gordon J; Burdo TH; Wollebo HS; Gianti E; Donadoni M; Bellizzi A; Cicalese S; Loomis R; Robinson JA; Carnevale V; Steiner J; Ozdener MH; Miller AD; Amini S; Klein ML; Khalili K
    Mol Ther; 2019 Dec; 27(12):2067-2079. PubMed ID: 31653397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.
    Melody K; McBeth S; Kline C; Kashuba AD; Mellors JW; Ambrose Z
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7762-70. PubMed ID: 26438501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
    Melody K; Roy CN; Kline C; Cottrell ML; Evans D; Shutt K; Pennings PS; Keele BF; Bility M; Kashuba ADM; Ambrose Z
    J Virol; 2020 Mar; 94(8):. PubMed ID: 31969438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation and pharmacology of long-acting rilpivirine.
    Williams PE; Crauwels HM; Basstanie ED
    Curr Opin HIV AIDS; 2015 Jul; 10(4):233-8. PubMed ID: 26049947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.
    Penrose KJ; Brumme CJ; Scoulos-Hanson M; Hamanishi K; Gordon K; Viana RV; Wallis CL; Harrigan PR; Mellors JW; Parikh UM
    Antivir Chem Chemother; 2018; 26():2040206618762985. PubMed ID: 29566538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.
    Vannappagari V; Ragone L; Henegar C; van Wyk J; Brown D; Demarest J; Quercia R; St Clair M; Underwood M; Gatell JM; de Ruiter A; Aboud M
    Antivir Ther; 2019; 24(6):393-404. PubMed ID: 31503008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An unusual case of underlying rilpivirine resistance in an antiretroviral-naïve man with AIDS.
    Skalweit MJ
    Int J STD AIDS; 2016 Dec; 27(14):1346-1349. PubMed ID: 27074792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV.
    Qazzaz H; Parganas C; Cory TJ
    Expert Opin Pharmacother; 2022 Sep; 23(13):1485-1495. PubMed ID: 36124818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.
    Hayashida T; Hachiya A; Ode H; Nishijima T; Tsuchiya K; Sugiura W; Takiguchi M; Oka S; Gatanaga H
    J Antimicrob Chemother; 2016 Oct; 71(10):2760-6. PubMed ID: 27330069
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Giacobbi NS; Sluis-Cremer N
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28507107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
    Llibre JM; Hung CC; Brinson C; Castelli F; Girard PM; Kahl LP; Blair EA; Angelis K; Wynne B; Vandermeulen K; Underwood M; Smith K; Gartland M; Aboud M
    Lancet; 2018 Mar; 391(10123):839-849. PubMed ID: 29310899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rilpivirine resistance associated mutations in HIV-1 infected pregnant women.
    Cecchini DM; Zapiola I; Rodriguez CG; Bouzas MB
    Enferm Infecc Microbiol Clin; 2015; 33(7):498-9. PubMed ID: 25639908
    [No Abstract]   [Full Text] [Related]  

  • 16. Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.
    James C; Preininger L; Sweet M
    Am J Health Syst Pharm; 2012 May; 69(10):857-61. PubMed ID: 22555080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
    La Regina G; Coluccia A; Silvestri R
    Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
    Schafer JJ; Short WR
    Antivir Ther; 2012; 17(8):1495-502. PubMed ID: 22878339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons.
    Calvez V; Marcelin AG; Vingerhoets J; Hill A; Hadacek B; Moecklinghoff C
    Antivir Ther; 2016; 21(5):405-12. PubMed ID: 26761642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India.
    Saravanan S; Kausalya B; Gomathi S; Sivamalar S; Pachamuthu B; Selvamuthu P; Pradeep A; Sunil S; Mothi SN; Smith DM; Kantor R
    AIDS Res Hum Retroviruses; 2017 Jun; 33(6):567-574. PubMed ID: 27869478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.